Surrogate to predict overall survival in patients with <i>BRAF</i> V600E-mutant colorectal cancer treated with BRAF inhibitor combinations.

ABSTRACT:

Background

The BRAF V600E mutation, found in up to 12% of patients with metastatic colorectal cancer, is associated with aggressive disease and poor response to standard chemotherapy. However, the advent of BRAF inhibitors has led to improved clinical outcomes and survival. While surrogate endpoints for predicting overall survival (OS) have been extensively studied in the overall colorectal cancer population treated with chemotherapy, their applicability in patients with BRAF V600E-mutant colorectal cancer receiving either BRAF inhibitor combinations or conventional chemotherapy remains unclear, and needs to be better elucidated. The aim of the study was to evaluate surrogate endpoints to predict OS in patients with BRAF V600E-mutant colorectal cancer treated w

SUBMITTER: Ros J 

PROVIDER: S-EPMC12836797 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature